Fixed‐dose combination aclidinium/formoterol vs placebo
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
- Combined aclidinium bromide and long‐acting beta2‐agonist for chronic obstructive pulmonary disease (COPD) 2018 · Cochrane Headline outcomes onlyOR 1.12 [0.72, 1.74]4 studies · 2527 participantsModerate